XENTHYA
AI-Programmable Biotherapeutics
AI-Programmable Biotherapeutics
Smart Medicine for a New Era
Xenthya is pioneering Generation 3 Biotherapeutics. By merging cloud-scale AI with synthetic biology, we design programmable artificial nanobodies and live biotherapeutic products with unprecedented precision.
The Next Evolutionary Step in Medicine. We are moving past the limitations of traditional small molecules and biologics toward a future of programmable healing.
Our cloud-native platform uses advanced protein folding algorithms to design artificial nanobodies from the ground up, reducing R&D timelines from years to months.
By optimizing specificity at the computational stage, Xenthya medicines minimize systemic toxicity, delivering therapeutic payloads exactly where they are needed.
Hyper-specific targeting with multi-valent binding capabilities enables treatment of previously undruggable targets.
At Xenthya, we believe the future of medicine lies in programmability. Our mission is to transform how therapeutic proteins are discovered, designed, and delivered.
While Generation 1 (small molecules) and Generation 2 (biologics) have revolutionized medicine, they face fundamental limitations in specificity, delivery, and manufacturability. Our Generation 3 approach combines the best of both worlds with AI-driven design.
Hyper-targeted nanobodies for solid tumor penetration with enhanced tissue distribution.
Programmable suppression of auto-immune pathways with precise cellular targeting.
Combating antimicrobial resistance (AMR) with engineered specificity against evolving pathogens.
Our artificial nanobodies represent a breakthrough in therapeutic protein design. Unlike traditional antibodies, nanobodies are single-domain proteins derived from camelid antibodies, offering unique advantages for therapeutic applications.
Xenthya's AI platform designs synthetic nanobodies with custom-engineered properties:
| Property | Traditional Antibodies | Xenthya Synthetic Nanobodies |
|---|---|---|
| Size | ~150 kDa | ~15 kDa (10x smaller) |
| Tissue Penetration | Limited | Deep tissue penetration |
| Thermal Stability | Moderate | High (up to 80°C) |
| Production Cost | High (mammalian cells) | Low (microbial fermentation) |
| Design Time | 12-24 months | 2-6 months |
Our nanobodies bind to disease-causing proteins with picomolar affinity, blocking pathological interactions while sparing normal physiological function.
Nanobodies serve as precision delivery vehicles for cytotoxic payloads, radioisotopes, or imaging agents directly to disease sites.
We engineer bi- and tri-specific nanobodies that simultaneously engage multiple targets for enhanced therapeutic efficacy.
Live Biotherapeutic Products represent a paradigm shift in how we deliver therapeutics. Xenthya engineers microbial chassis to produce and deliver smart biotherapeutics directly at the site of action.
Our LBP platform combines synthetic biology with microbiome science to create living medicines:
Engineered probiotics survive gastric transit and colonize the gut mucosa, providing sustained local production of therapeutic nanobodies without the need for IV administration.
Our microbial chassis are programmed to release therapeutics in response to specific environmental cues (pH, metabolites, inflammation markers).
Oral administration dramatically improves patient compliance compared to injectable biologics, especially for chronic conditions requiring long-term treatment.
Traditional biologics require cold chain storage, clinical administration, and carry immunogenicity risks. Our LBP platform offers room-temperature stable, self-administered therapeutics that work in harmony with the patient's own microbiome.
We are looking for strategic partners and visionary collaborators to bring Generation 3 Biotherapeutics to the patients who need them most.
Inquire for Partnerships